相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer
Emmanuelle Wesarg et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo
Min H. Kang et al.
BLOOD (2007)
'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737
X. Lin et al.
ONCOGENE (2007)
Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex
Barry J. Maurer et al.
CLINICAL CANCER RESEARCH (2007)
A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma
D. Chauhan et al.
ONCOGENE (2007)
A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations
Tomas Frgala et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737
Stephen K. Tahir et al.
CANCER RESEARCH (2007)
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing bak activation and bax translocation
Shuang Chen et al.
CANCER RESEARCH (2007)
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737
Victoria Del Gaizo Moore et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML
Kensuke Kojima et al.
CELL CYCLE (2006)
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
Mark F. van Delft et al.
CANCER CELL (2006)
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
Marina Konopleva et al.
CANCER CELL (2006)
A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo
Alex R. Shoemaker et al.
CANCER RESEARCH (2006)
Phase I trial of oral fenretinide in children with high-risk solid tumors: A report from the Children's Oncology Group (CCG 09709)
Judith G. Villablanca et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Upregulation of Bfl-1/A1 in leukemia cells undergoing differentiation by all-trans retinoic acid treatment attenuates chemotherapeutic agent-induced apoptosis
L. Xia et al.
LEUKEMIA (2006)
N-(4-hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells
HJ Kim et al.
ONCOGENE (2006)
Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias
G Tabellini et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Apoptosis-based therapies for hematologic malignancies
JC Reed et al.
BLOOD (2005)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
Tirapazamine cytotoxicity for neuroblastoma is p53 dependent
B Yang et al.
CLINICAL CANCER RESEARCH (2005)
Phase II trial of fenretinide in advanced renal carcinoma
U Vaishampayan et al.
INVESTIGATIONAL NEW DRUGS (2005)
N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines
M Cuello et al.
CELL DEATH AND DIFFERENTIATION (2004)
Phase II study of Fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American brain tumor consortium study
VK Puduvalli et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Fenretinide induces sustained-activation of JNK/p38 MAPK and apoptosis in a reactive oxygen species-dependent manner in neuroblastoma cells
S Osone et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Phosphorylation and inactivation of myelbid cell leukemia 1 by JNK in response to oxidative stress
S Inoshita et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis
SR Datta et al.
DEVELOPMENTAL CELL (2002)
N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes
PH O'Donnell et al.
LEUKEMIA (2002)
The c-Jun N-terminal protein kinase family of mitogen-activated protein kinases (JNK MAPKs)
RK Barr et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2001)
Retinoid therapy of childhood cancer
CP Reynolds et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2001)
BCL-2, BCL-XL sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis
EHYA Cheng et al.
MOLECULAR CELL (2001)
Short tandem repeat profiling provides an international reference standard for human cell lines
JR Masters et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death
MC Wei et al.
SCIENCE (2001)
Chemoprevention of breast cancer with fenretinide
R Torrisi et al.
DRUGS (2001)
Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism
BJ Maurer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c
SJ Korsmeyer et al.
CELL DEATH AND DIFFERENTIATION (2000)
分享论文
